About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the ...

This release fulfills the Company's October 20 announcement that next-round results on the expanded human-submitted dataset ...

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization ...

Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in ...

Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary ...

Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize ...

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today ...

Bioscience employment rose in 41 states, though not in California, according to a new report from the Biotechnology ...

After a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec ...

CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on ...

In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who ...